Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of maridebart cafraglutide in Chinese adults with obesity or overweight with weight-related comorbidities
CTR20264119Phase 3Active
- Sponsor
- Amgen
- Start
- Nov 2026
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of maridebart cafraglutide in obesity, Overweight, sponsored by Amgen. Started Nov 2026; status: active.
02
Drugs
maridebart cafraglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20264119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264119.